Abaloparatide, a selective activator of the parathyroid hormone receptor, has recently been shown to reduce fractures in postmenopausal women with osteoporosis. Now new research shows that abaloparatide increases bone mass in rats whose ovaries have been removed by stimulating bone formation, without effects on bone resorption.
"These preclinical data support the continued development of abaloparatide as a treatment to reduce fracture risk in patients with osteoporosis," wrote the authors of the Journal of Bone and Mineral Research study.
###
Journal of Bone and Mineral Research